“The drug development landscape in Parkinson’s” by Dr Kevin McFarthing

[Michel0220]

I am delighted to announce our next zoom session that will be taking place at 7.30 pm London time on Monday, the 25th of April.

We will have the pleasure of listening to Dr Kevin McFarthing who will update us on “The drug development landscape in Parkinson’s”.

The presentation will give an overview of research and clinical development for Parkinson’s, starting with an overview of trends. The 350+ active projects will be categorised by their position on the road to the patient and the objective, whether it is for symptom relief or disease modification. Finally, some exciting options will be discussed in more detail.

Please use the Eventbrite link below to register for this event:

eventbrite.co.uk/e/31481639...

Originally a PhD biochemist, Dr Kevin McFarthing’s career included R&D leadership positions in life sciences research products with Amersham, diagnostics with Serono and consumer healthcare with Reckitt Benckiser.

He is joint editor of the Clinical Trial Highlights section of the Journal of Parkinson’s Disease and a member of the Research Committee of Cure Parkinson’s, and is first author on a recent review of the clinical trial pipeline in Parkinson’s (content.iospress.com/articl... ).

Kevin collates the Parkinson’s Hope List (bit.ly/ParkinsonsHopeList), a database of potential therapies in research and clinical stages.

He also chairs the Patient and Public Involvement and Engagement group for the Edmond J Safra Accelerating Clinical Trials in Parkinson’s Disease program.

Kevin was diagnosed with Parkinson’s in 2012 at the age of 55.

[Zella23]

Thank you for posting this. Sounds very interesting. We ll be watching!

[Michel0220 in reply to Zella23]

It is with pleasure, thank you Zella.